TD Cowen cuts Danaher stock price target to $240 on mixed quarter

The setup is less about one quarter and more about whether the sector is in the early innings of a second-half inflection or just experiencing a dead-cat bounce. In tools/life sciences, the stock is now pricing in a fairly normal recovery, but the market is still demanding proof that bioprocessing and research budgets are reaccelerating simultaneously; that is a high bar because those end markets tend to turn at different speeds. If China improves first, it can help sentiment quickly, but it is usually not enough by itself to sustain multiple expansion unless U.S. biopharma capex also inflects.

The key second-order issue is positioning: when a high-quality compounder underperforms on a modest guide miss, the selloff often becomes self-reinforcing because passive and factor-driven holders de-risk before fundamentals fully turn. That creates a tactical opportunity, but only if the next data points confirm that the demand weakness was transitory rather than a normalization of post-pandemic digestion. The risk is that investors are anchoring to a back-half ramp that management can describe but not yet monetize in orders, which would keep the name range-bound for another 1-2 quarters.

The cleanest contrarian read is that the stock may have overshot to the downside relative to its operating resilience. Earnings power held up better than revenue, suggesting margin discipline can partially cushion a slower top line, and that matters in a sector where sentiment typically re-rates before fundamentals do. But upside from here likely needs a catalyst cluster: order improvement, China stabilization, and evidence that bioproduction equipment is not just a one-off rebound but a multi-quarter cycle turn.

For competitors, a lingering reset in tools spending can pressure smaller, less diversified names harder than the large platform players, because purchasing teams tend to consolidate vendors toward breadth and service quality during budget scrutiny. That favors scaled incumbents with recurring consumables/service mix and penalizes pure-play instrument vendors if the recovery is choppy.